Characteristics | Year 1 progress reports (n = 91) | Year 2 progress reports (n = 144) | Total (N = 235) |
---|---|---|---|
Partner communities engaged a(n, %) | |||
Clinician | 83 (91%) | 126 (88%) | 209 (89%) |
Patient/consumer | 82 (90%) | 125 (87%) | 207 (88%) |
Patient/caregiver advocacy organization | 56 (62%) | 84 (58%) | 140 (60%) |
Clinic/hospital/ health system representative | 53 (58%) | 81 (56%) | 134 (57%) |
Caregiver/family member of patient | 43 (47%) | 77 (53%) | 120 (51%) |
Subject matter expertb | 43 (47%) | 78 (54%) | 121 (51%) |
Training institution representativec (non-research health professions including educator) | 15 (16%) | 22 (15%) | 37 (16%) |
Policy maker (government official) | 10 (11%) | 28 (19%) | 38 (16%) |
Payer (public or private insurance) | 13 (14%) | 22 (15%) | 35 (15%) |
Life sciences industry representative | 2 (2%) | 9 (6%) | 11 (5%) |
Purchaser of insurance plans (small or large employers) | 0 (0%) | 5 (3%) | 5 (2%) |
Other d | 26 (29%) | 68 (47%) | 94 (40%) |
Approaches to engaging partners a (n, %) | |||
Patient/stakeholder research team members | 74 (81%) | 118 (82%) | 192 (82%) |
➢ Team members as co-investigators e | 44 (59%) | 63 (53%) | 107 (56%) |
Advisory groups | 72 (79%) | 123 (85%) | 195 (83%) |
Opinion polls, surveys or interviews | 39 (43%) | 53 (37%) | 92 (39%) |
Other f | 4 (4%) | 13 (9%) | 17 (7%) |
Study phases in which partners were engaged a (n, %) | |||
Research topics and/or research questions | 54 (59%) | 90 (63%) | 144 (61%) |
Interventions and/or comparators | 62 (68%) | 101 (70%) | 163 (69%) |
Outcomes and/or measurement | 71 (78%) | 106 (74%) | 177 (75%) |
Other aspects of study design | 61 (67%) | 94 (65%) | 155 (66%) |
Recruitment and/or retention | 53 (58%) | 97 (67%) | 150 (64%) |
Data collection | 29 (32%) | 64 (44%) | 93 (40%) |
Data analysis and/or results review | 34 (37%) | 98 (68%) | 132 (56%) |
Dissemination | 24 (26%) | 77 (53%) | 101 (43%) |